PANACEABIO388.00

Panacea Biotec Limited

· Pharma & Health
AnnualQuarterly₹ CrorePeersSAIPARENTHIKALINDOCODCALWINDLASHESTERBIOSOLARASYNCOMFMcap ₹2,378 Cr
View
In ₹ Crore except Per Share
12 Months Ending
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Revenue from Operations559.2559.1639.8672.6
Other Income25.820.716.915.5
Total Income585.0579.8656.7688.1
Expenses
+ Cost of Materials Consumed210.5214.1290.2291.7
+ Purchases of Stock-in-Trade1.87.69.07.7
+ Changes in Inventories17.9-22.1-18.75.5
+ Employee Benefit Expense149.6173.1180.8179.2
+ Finance Costs3.63.96.16.4
+ Depreciation & Amortisation36.734.833.132.6
+ Other Expenses199.5212.4183.2186.3
Total Expenses619.5623.7683.5709.4
EBITDA-20.1-25.9-4.72.2
EBIT-56.8-60.7-37.7-30.4
Profit
PBT before Exceptional Items-34.6-43.9-26.9-21.3
+ Exceptional Items36.036.019.510.9
Pretax Income1.5-8.0-7.4-10.4
+ Current Tax0.70.00.40.8
+ Deferred Tax2.30.8-0.6-2.3
Tax Expense3.00.8-0.2-1.4
Net Income-1.5-8.7-7.2-8.9
+ Net Income — Continuing Ops-1.5-8.7-7.2-8.9
+ Other Comprehensive Income-0.41.15.45.8
Total Comprehensive Income-1.9-7.6-1.7-3.1
Net Income to Common-1.2-8.4-5.4-7.1
Minority Interest-0.3-0.4-1.8-1.8
Per Share
Basic EPS-0.19-1.37-0.88-1.16
Diluted EPS-0.19-1.37-0.88-1.16
Other Comprehensive Income — detail
+ Other Comprehensive Income1.15.45.8
+ Items NOT to be Reclassified to P&L-0.5-0.12.02.6
+ Tax on Items NOT to be Reclassified-0.00.50.7
+ Tax on Items NOT to be Reclassified — alt tag-0.1
+ Items to be Reclassified to P&L-0.11.23.9
Comprehensive Income — Owners of Parent-1.6-7.30.1-1.3
Comprehensive Income — Non-controlling Interests-0.3-0.4-1.8-1.8
Per Share — as-filed variants
Basic EPS — Continuing Operations-0.19-1.37-0.88-1.16
Diluted EPS — Continuing Operations-0.19-1.37-0.88-1.16
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit329.1359.6359.3367.7
Gross Margin %58.8564.3156.1654.66
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)-34.6-43.9-26.9-21.3
− Exceptional Items (reconciliation)36.036.019.510.9
Net Income Adj (tax-effected)-15.9-44.7-26.1-18.3
EPS Adj-2.02-7.02-3.21-2.38
Other Filed Concepts — mapped but not yet placed in the schedule
Face Value1.001.001.001.00
Paid Up Equity Capital6.16.16.16.1
As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.